Evaluation of plasmatic MMP-8, MMP-9, TIMP-1 and MPO levels in obese and lean women

Clinical Biochemistry

Volumn 45, Issue 6, 2012, Pages 412-415

  Andrade, Vanessa L ^a   Petruceli, Eveline ^a   Belo, Vanessa A ^b   Andrade Fernandes, Claudia M ^c   Caetano Russi, Cristiane V ^c   Bosco, Adriana Ap ^a   Tanus Santos, José Eduardo ^b   Sandrim, Valeria Cristina ^a  

^a Nucleo de Pos Graduacao e Pesquisa   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Santa Casa de Belo Horizonte   (Brazil)

Author keywords

MMP 8; MMP 9; MPO; Neutrophil activation; Neutrophil collagenase; Obesity; TIMP 1

Indexed keywords

GELATINASE B; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYELOPEROXIDASE; NEUTROPHIL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; COLORIMETRY; COMORBIDITY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INTERMETHOD COMPARISON; LEAN BODY WEIGHT; LEUKOCYTE ACTIVATION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; OBESITY; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; FEMALE; HUMANS; MATRIX METALLOPROTEINASE 8; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; OBESITY; PEROXIDASE; THINNESS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84858439276     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.01.008     Document Type: Article

References (33)

1. Mokdad A.H., Bowman B.A., Ford E.S., Vinicor F., Marks J.S., Koplan J.P. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001, 286:1195-1200.
2. Chudek J., Wiecek A. Adipose tissue, inflammation and endothelial dysfunction. Pharmacol Rep 2006, 58(Suppl):81-88.
3. Van Gaal L.F., Mertens I.L., De Block C.E. Mechanisms linking obesity with cardiovascular disease. Nature 2006, 444:875-880.
4. Halberg N., Wernstedt-Asterholm I., Scherer P.E. The adipocyte as an endocrine cell. Endocrinol Metab Clin North Am 2008, 37:753-768. (x-xi).
5. Garvin P., Nilsson L., Carstensen J., Jonasson L., Kristenson M. Circulating matrix metalloproteinase-9 is associated with cardiovascular risk factors in a middle-aged normal population. PLoS One 2008, 3:e1774.
6. Nilsson L, Hallen J, Atar D, Jonasson L, Swahn E. Early measurements of plasma matrix metalloproteinase-2 predict infarct size and ventricular dysfunction in st-elevation myocardial infarction. Heart.
7. Palei A.C., Sandrim V.C., Cavalli R.C., Tanus-Santos J.E. Comparative assessment of matrix metalloproteinase (mmp)-2 and mmp-9, and their inhibitors, tissue inhibitors of metalloproteinase (timp)-1 and timp-2 in preeclampsia and gestational hypertension. Clin Biochem 2008, 41:875-880.
8. Gerlach R.F., Meschiari C.A., Marcaccini A.M., Palei A.C., Sandrim V.C., Cavalli R.C., et al. Positive correlations between serum and plasma matrix metalloproteinase (mmp)-2 or mmp-9 levels in disease conditions. Clin Chem Lab Med 2009, 47:888-891.
9. Loftus I.M., Naylor A.R., Goodall S., Crowther M., Jones L., Bell P.R., et al. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke 2000, 31:40-47.
10. Kosmala W., Plaksej R., Przewlocka-Kosmala M., Kuliczkowska-Plaksej J., Bednarek-Tupikowska G., Mazurek W. Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: relationship to cardiac function. Int J Obes (Lond) 2008, 32:763-771.
11. Laimer M., Kaser S., Kranebitter M., Sandhofer A., Muhlmann G., Schwelberger H., et al. Effect of pronounced weight loss on the nontraditional cardiovascular risk marker matrix metalloproteinase-9 in middle-aged morbidly obese women. Int J Obes (Lond) 2005, 29:498-501.
12. Goncalves F.M., Jacob-Ferreira A.L., Gomes V.A., Casella-Filho A., Chagas A.C., Marcaccini A.M., et al. Increased circulating levels of matrix metalloproteinase (mmp)-8, mmp-9, and pro-inflammatory markers in patients with metabolic syndrome. Clin Chim Acta 2009, 403:173-177.
13. Kato R., Momiyama Y., Ohmori R., Taniguchi H., Nakamura H., Ohsuzu F. Plasma matrix metalloproteinase-8 concentrations are associated with the presence and severity of coronary artery disease. Circ J 2005, 69:1035-1040.
14. Aquilante C.L., Beitelshees A.L., Zineh I. Correlates of serum matrix metalloproteinase-8 (mmp-8) concentrations in nondiabetic subjects without cardiovascular disease. Clin Chim Acta 2007, 379:48-52.
15. Tuomainen A.M., Nyyssonen K., Laukkanen J.A., Tervahartiala T., Tuomainen T.P., Salonen J.T., et al. Serum matrix metalloproteinase-8 concentrations are associated with cardiovascular outcome in men. Arterioscler Thromb Vasc Biol 2007, 27:2722-2728.
16. Goldberg G.I., Strongin A., Collier I.E., Genrich L.T., Marmer B.L. Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem 1992, 267:4583-4591.
17. Klebanoff S.J. Myeloperoxidase: contribution to the microbicidal activity of intact leukocytes. Science 1970, 169:1095-1097. (New York, NY).
18. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
19. Bradley P.P., Priebat D.A., Christensen R.D., Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 1982, 78:206-209.
20. Bouloumie A., Sengenes C., Portolan G., Galitzky J., Lafontan M. Adipocyte produces matrix metalloproteinases 2 and 9: involvement in adipose differentiation. Diabetes 2001, 50:2080-2086.
21. Blankenberg S., Rupprecht H.J., Poirier O., Bickel C., Smieja M., Hafner G., et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003, 107:1579-1585.
22. Momiyama Y, Ohmori R, Tanaka N, Kato R, Taniguchi H, Adachi T, et al. High plasma levels of matrix metalloproteinase-8 in patients with unstable angina. Atherosclerosis.209:206-10.
23. Belo V.A., Souza-Costa D.C., Lana C.M., Caputo F.L., Marcaccini A.M., Gerlach R.F., et al. Assessment of matrix metalloproteinase (mmp)-2, mmp-8, mmp-9, and their inhibitors, the tissue inhibitors of metalloproteinase (timp)-1 and timp-2 in obese children and adolescents. Clin Biochem 2009, 42:984-990.
24. Zile MR, Desantis SM, Baicu CF, Stroud RE, Thompson SB, McClure CD, et al. Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail.4:246-56.
25. Owen C.A., Hu Z., Lopez-Otin C., Shapiro S.D. Membrane-bound matrix metalloproteinase-8 on activated polymorphonuclear cells is a potent, tissue inhibitor of metalloproteinase-resistant collagenase and serpinase. J Immunol 2004, 172:7791-7803.
26. Maquoi E., Munaut C., Colige A., Collen D., Lijnen H.R. Modulation of adipose tissue expression of murine matrix metalloproteinases and their tissue inhibitors with obesity. Diabetes 2002, 51:1093-1101.
27. O'Hara A., Lim F.L., Mazzatti D.J., Trayhurn P. Microarray analysis identifies matrix metalloproteinases (mmps) as key genes whose expression is up-regulated in human adipocytes by macrophage-conditioned medium. Pflugers Arch 2009, 458:1103-1114.
28. Lin Y., Nakachi K., Ito Y., Kikuchi S., Tamakoshi A., Yagyu K., et al. Variations in serum transforming growth factor-beta1 levels with gender, age and lifestyle factors of healthy Japanese adults. Dis Markers 2009, 27:23-28.
29. Palosaari H., Wahlgren J., Larmas M., Ronka H., Sorsa T., Salo T., et al. The expression of mmp-8 in human odontoblasts and dental pulp cells is down-regulated by tgf-beta1. J Dent Res 2000, 79:77-84.
30. Tjaderhane L., Salo T., Larjava H., Larmas M., Overall C.M. A novel organ culture method to study the function of human odontoblasts in vitro: gelatinase expression by odontoblasts is differentially regulated by tgf-beta1. J Dent Res 1998, 77:1486-1496.
31. Nijhuis J., Rensen S.S., Slaats Y., van Dielen F.M., Buurman W.A., Greve J.W. Neutrophil activation in morbid obesity, chronic activation of acute inflammation. Obesity (Silver Spring) 2009, 17:2014-2018.
32. Nicholls S.J., Hazen S.L. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 2005, 25:1102-1111.
33. Izidoro-Toledo TC, Guimaraes DA, Belo VA, Gerlach RF, Tanus-Santos JE. Effects of statins on matrix metalloproteinases and their endogenous inhibitors in human endothelial cells. Naunyn-Schmiedeberg's archives of pharmacology.383:547-54.